{"id":96249,"date":"2024-08-13T13:09:29","date_gmt":"2024-08-13T13:09:29","guid":{"rendered":"https:\/\/www.mymsd.ch\/fr\/?page_id=96249"},"modified":"2026-04-10T14:14:43","modified_gmt":"2026-04-10T14:14:43","slug":"keytruda","status":"publish","type":"page","link":"https:\/\/www.mymsd.ch\/fr\/succinctstatement\/keytruda\/","title":{"rendered":"Information professionnelle KEYTRUDA\u00ae (pembrolizumab)"},"content":{"rendered":"\n<h1 class=\"wp-block-heading  has-border-color has-has-red-border-color-border-color has-teal-500-color has-text-color mhh-mcn-v1-heading--left mhh-mcn-v1-heading mhh-mcn-v1-heading--de4e7645a2c3e6785f36f4844085a83e\">Information professionnelle abr\u00e9g\u00e9e de KEYTRUDA\u00ae (pembrolizumab)<\/h1>\n\n\n\n<p class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--c00b045897b1b705e45da3366f5b9752\"><strong>KEYTRUDA\u00ae: C:<\/strong> pembrolizumab<strong>. I:<\/strong> adultes: monoth\u00e9rapie indiqu\u00e9e pour le traitement d\u2019un m\u00e9lanome non r\u00e9s\u00e9cable ou m\u00e9tastatique et pour le traitement adjuvant du m\u00e9lanome de stade III enti\u00e8rement r\u00e9s\u00e9qu\u00e9. Autorisation temporaire: en monoth\u00e9rapie dans le traitement adj. d\u2019un m\u00e9lanome de stade IIB ou IIC enti\u00e8rement r\u00e9s\u00e9qu\u00e9. <strong>Po:<\/strong> adultes: <a>200 mg i.v. 30 min. toutes les 3 semaines<\/a> ou 400 mg i.v. 30 min. toutes les 6 semaines; traitement jusqu&rsquo;\u00e0 la progression de la maladie, resp. l&rsquo;apparition d&rsquo;une r\u00e9cidive, ou jusqu&rsquo;\u00e0 une toxicit\u00e9 intol\u00e9rable; pour 12 mois au maximum en cas de m\u00e9lanome en adjuvant. <strong><em>Pour d&rsquo;autres indications et les dosages correspondants pour les adultes et les patients p\u00e9diatriques, veuillez vous r\u00e9f\u00e9rer \u00e0 l&rsquo;information professionnelle.<\/em><\/strong> <strong>CI:<\/strong> hypersensibilit\u00e9 au principe actif\/excipients.<strong> Pr: <\/strong>effets ind\u00e9sirables d\u2019origine immunologique: notamment pneumopathie inflammatoire, colite, h\u00e9patite, n\u00e9phrite, endocrinopathies (y compris hypophysite, diab\u00e8te de type 1, troubles thyro\u00efdiens; dans TNBC surveiller le taux de cortisol), lymphohistiocytose h\u00e9mophagocytaire (LHH), r\u00e9actions cutan\u00e9es s\u00e9v\u00e8res (syndrome de Stevens-Johnson,de n\u00e9crolyse \u00e9pidermique toxique, syndrome DRESS), autres effets ind\u00e9sirables d&rsquo;origine immunologique; patients atteints d&rsquo;une maladie auto-immune pr\u00e9existante; transplantation \/ transplantation de cellules souches (TCSH): \u00abgraft-versus-host-disease\u00bb (GVHD) et maladie veino-occlusive h\u00e9patique (VOD); th\u00e9rapie adjuvante du m\u00e9lanome IIB\/IIC et CPNPC IB\/II\/IIIA: analyse d\u2019OS en attente; traitement adjuvant apr\u00e8s un traitement n\u00e9oadjuvant associ\u00e9 \u00e0 une toxicit\u00e9 plus importante; l&rsquo;impact sur la th\u00e9rapie syst\u00e9mique \u00e0 base d\u2019anti-PD-(L)1 r\u00e9administr\u00e9 ult\u00e9rieurement, y compris des r\u00e9sistances en cas de r\u00e9cidive, n&rsquo;a pas \u00e9t\u00e9 \u00e9tudi\u00e9; \u00e9l\u00e9vation des enzymes h\u00e9patiques lorsque <a>KEYTRUDA\u00ae<\/a> est associ\u00e9 \u00e0 l\u2019axitinib (surveiller les enzymes h\u00e9patiques avant l\u2019initiation du traitement et tout au long de celui-ci); infarctus du myocarde lors de l&#8217;emploi de KEYTRUDA\u00ae en association avec le lenvatinib en cas de CCR; my\u00e9lome multiple: augmentation de la mortalit\u00e9 en combinaison avec KEYTRUDA\u00ae, d&rsquo;analogue du thalidomide et de dexamethasone; association avec le trastuzumab dans le carcinome gastrique, voir l\u2019information professionnelle de trastuzumab; donn\u00e9es sur les traitements ant\u00e9rieurs par immunoth\u00e9rapie pour certaines indications pas disponibles, ou de tels patients exclus des \u00e9tudes; r\u00e9actions li\u00e9es \u00e0 la perfusion (y compris d&rsquo;hypersensibilit\u00e9 et d&rsquo;anaphylaxie); patients ont \u00e9t\u00e9 exclus des essais cliniques (voir l\u2019information professionnelle pour plus de d\u00e9tails). <strong>IA:<\/strong> aucune connue\/n&rsquo;a fait l&rsquo;objet d&rsquo;une \u00e9tude. <strong>G\/A:<\/strong> non recommand\u00e9, contraception. <strong>EI:<\/strong> (tr\u00e8s fr\u00e9quents): Infections des voies respiratoires, infections des voies urinaires, an\u00e9mie, diminution du nombre de neutrophiles, neutrop\u00e9nie, thrombop\u00e9nie, hypothyro\u00efdie, diminution de l\u2019app\u00e9tit, hypokali\u00e9mie, perte de poids, hypomagn\u00e9s\u00e9mie, insomnie, c\u00e9phal\u00e9es, neuropathie p\u00e9riph\u00e9rique, dysgueusie, hypertension, h\u00e9morragies, dyspn\u00e9e, toux, dysphonie, diarrh\u00e9e, douleurs abdominales, naus\u00e9es, vomissements, constipation, augmentation du taux de lipase, inflammations orales, stomatite, ALAT augment\u00e9e, ASAT augment\u00e9e, rash cutan\u00e9, \u00e9ruption maculopapuleuse, prurit, alop\u00e9cie, syndrome d`\u00e9rythrodysesth\u00e9sie palmo-plantaire, douleurs musculosquelettiques, arthralgie, myosite, douleurs aux extr\u00e9mit\u00e9s, prot\u00e9inurie, cr\u00e9atinine sanguine augment\u00e9e, fatigue\/\u00e9puisement, asth\u00e9nie, \u0153d\u00e8mes, pyrexie. <strong>P:<\/strong> 2 flacons perforables \u00e0 100mg \/ 4ml. <strong>CR:<\/strong> A. <strong>Td\u2019a:<\/strong> MSD Merck Sharp &amp; Dohme AG, B\u00fcrgenstrasse 8, 6005 Lucerne, Suisse. (V29.0); CH-KEY-00084.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-gray-300-color has-alpha-channel-opacity has-gray-300-background-color has-background\" \/>\n\n\n\n<p dir=\"ltr\" lang=\"fr-FR\" class=\"has-border-color has-has-red-border-color-border-color has-object-object-font-size   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--654b997fc4417046fa4a52b92460a103\"><em>&nbsp;Avant de prescrire, veuillez consulter l\u2019information professionnelle compl\u00e8te publi\u00e9e sur la page d\u2019accueil de Swissmedic&nbsp;<a href=\"https:\/\/www.swissmedicinfo-pro.ch\/ShowText.aspx?textType=FI&amp;lang=FR&amp;authNr=66231\" target=\"_blank\" rel=\"noreferrer noopener\">www.swissmedicinfo-pro.ch<\/a>.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Information professionnelle abr\u00e9g\u00e9e de KEYTRUDA\u00ae (pembrolizumab) KEYTRUDA\u00ae: C: pembrolizumab. I: adultes: monoth\u00e9rapie indiqu\u00e9e pour le traitement d\u2019un m\u00e9lanome non r\u00e9s\u00e9cable [&hellip;]<\/p>\n","protected":false},"author":73173,"featured_media":0,"parent":96214,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_mhh_sticky_footer_settings":{"entityId":0},"_mhh_sticky_footer_posts":"","_mhh_sticky_footer_expanded":false,"_mhh_mcn_text_direction":"","_mhh_mcn_language":"","_mhh_mcn_left_sidebar_settings":{"entityId":0},"_mhh_mcn_sidebar_settings":{"entityId":0},"mhh_mcn_side_navigation_style":{"fontSize":{"l":"","m":"","s":""},"lineHeight":{"l":1.5,"m":1.5,"s":1.5},"itemColor":"","hoverItemColor":"","currentItemColor":"","borderItemColor":"","backgroundItemHoverColor":"","themeColor":""},"_mhh_mcn_child_page_navigation":{"isActive":false,"isSticky":false},"hide_header":false,"show_top_bar":false,"hide_footer":false,"full_width_layout":false,"icon":null,"job_code":"","primary_tag":1608,"editor_notices":[],"mconnectHideShareThis":false,"footnotes":"","mconnectIsArchiveTemplate":false,"mconnectArchiveFiltersDisabled":false,"mconnectArchiveLockAllPresetFilters":false,"mconnectArchiveHidePageSubmenu":false,"mconnectArchiveShowParentPageOnly":false,"mconnectArchiveDefaultOrder":"DESC","mconnectArchiveDefaultOrderBy":"date","mconnectArchivePostsPerPage":12,"mconnectArchivePostTypes":[],"mconnectArchiveAllowFilterBy":["category","tx-content-type","tx-product","tx-pathology","tx-active-ingredient","tx-therapeutic-area"],"mconnectArchiveTaxonomyOrder":[],"mconnectArchiveFilterSorting":["active","is_keyword","is_date"],"mconnectArchiveContentItemStyle":{"showExcerpt":true,"showImage":true,"showIcon":false,"showPrimaryTag":true,"showBorder":false,"showDates":false,"showCta":true,"isCard":false,"hasBackground":false,"showMetadata":true},"mconnectArchiveLayout":{"type":"list","hasFeatured":false},"mconnectDynamicTaxonomyEntities":[],"mconnectArchiveTerms_category":[],"mconnectArchiveAllowTerms_category":[],"mconnectArchiveTerms_tx-content-type":[],"mconnectArchiveAllowTerms_tx-content-type":[],"mconnectArchiveTerms_tx-product":[],"mconnectArchiveAllowTerms_tx-product":[],"mconnectArchiveTerms_tx-pathology":[],"mconnectArchiveAllowTerms_tx-pathology":[],"mconnectArchiveTerms_tx-active-ingredient":[],"mconnectArchiveAllowTerms_tx-active-ingredient":[],"mconnectArchiveTerms_tx-therapeutic-area":[],"mconnectArchiveAllowTerms_tx-therapeutic-area":[],"mconnectArchiveAllowTerms_dynamic-taxonomy":[],"mconnectArchiveLegacyDefaultTermsApplied":false,"mconnectContentUpdatesPerPage":10,"mconnectContentUpdatesViewMoreUrl":"","mconnectContentUpdatesTerms_tx-content-type":[],"mconnectContentUpdatesTerms_tx-product":[],"mconnectContentUpdatesTerms_tx-pathology":[],"mconnectContentUpdatesTerms_tx-active-ingredient":[],"mconnectContentUpdatesTerms_tx-therapeutic-area":[],"sidebar_toogle":0,"sidebar_toogle_notification_warning":true,"sidebar_toogle_notification_alert":true,"content_expiration_sidebar_date":"","content_expiration_sidebar_expired_post_status":"","content_expiration_sidebar_redirection":""},"categories":[1607],"tags":[1608],"ga4_page_audience":[],"ga4_page_birn_id":[],"ga4_page_branding":[957],"ga4_page_businessunit":[963],"ga4_page_campaign":[],"ga4_page_content_purpose":[1535],"ga4_page_customer_journey_stage":[],"ga4_page_customer_specialty":[1052],"ga4_page_experience":[],"ga4_page_indication":[],"ga4_page_material_intent":[1206],"ga4_page_product":[1421],"ga4_page_region":[1462],"ga4_page_therapeuticarea":[1497],"tx-therapeutic-area":[627],"tx-product":[642],"tx-pathology":[],"tx-content-type":[1609],"tx-active-ingredient":[],"access":[],"user_status":[],"user_role":[],"class_list":["post-96249","page","type-page","status-publish","hentry","category-kfi","tag-kfi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Information professionnelle KEYTRUDA\u00ae (pembrolizumab) - MyMSD.ch FR<\/title>\n<meta name=\"robots\" content=\"noindex, nofollow\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Information professionnelle KEYTRUDA\u00ae (pembrolizumab) - MyMSD.ch FR\" \/>\n<meta property=\"og:description\" content=\"Information professionnelle abr\u00e9g\u00e9e de KEYTRUDA\u00ae (pembrolizumab) KEYTRUDA\u00ae: C: pembrolizumab. I: adultes: monoth\u00e9rapie indiqu\u00e9e pour le traitement d\u2019un m\u00e9lanome non r\u00e9s\u00e9cable [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.mymsd.ch\/fr\/succinctstatement\/keytruda\/\" \/>\n<meta property=\"og:site_name\" content=\"MyMSD.ch FR\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-10T14:14:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2022\/03\/02852_MSD_Logo_W-Anthem_Vertical_TealGrey_RGB.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2186\" \/>\n\t<meta property=\"og:image:height\" content=\"2134\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/succinctstatement\/keytruda\/\",\"url\":\"https:\/\/www.mymsd.ch\/fr\/succinctstatement\/keytruda\/\",\"name\":\"Information professionnelle KEYTRUDA\u00ae (pembrolizumab) - MyMSD.ch FR\",\"isPartOf\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#website\"},\"datePublished\":\"2024-08-13T13:09:29+00:00\",\"dateModified\":\"2026-04-10T14:14:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/succinctstatement\/keytruda\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.mymsd.ch\/fr\/succinctstatement\/keytruda\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/succinctstatement\/keytruda\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.mymsd.ch\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Product Succinct Statement\",\"item\":\"https:\/\/www.mymsd.ch\/fr\/succinctstatement\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Information professionnelle KEYTRUDA\u00ae (pembrolizumab)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#website\",\"url\":\"https:\/\/www.mymsd.ch\/fr\/\",\"name\":\"MyMSD.ch FR\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.mymsd.ch\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#organization\",\"name\":\"MSD Switzerland\",\"url\":\"https:\/\/www.mymsd.ch\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2023\/10\/cropped-myMSD-logo.png\",\"contentUrl\":\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2023\/10\/cropped-myMSD-logo.png\",\"width\":4084,\"height\":692,\"caption\":\"MSD Switzerland\"},\"image\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Information professionnelle KEYTRUDA\u00ae (pembrolizumab) - MyMSD.ch FR","robots":{"index":"noindex","follow":"nofollow"},"og_locale":"fr_FR","og_type":"article","og_title":"Information professionnelle KEYTRUDA\u00ae (pembrolizumab) - MyMSD.ch FR","og_description":"Information professionnelle abr\u00e9g\u00e9e de KEYTRUDA\u00ae (pembrolizumab) KEYTRUDA\u00ae: C: pembrolizumab. I: adultes: monoth\u00e9rapie indiqu\u00e9e pour le traitement d\u2019un m\u00e9lanome non r\u00e9s\u00e9cable [&hellip;]","og_url":"https:\/\/www.mymsd.ch\/fr\/succinctstatement\/keytruda\/","og_site_name":"MyMSD.ch FR","article_modified_time":"2026-04-10T14:14:43+00:00","og_image":[{"width":2186,"height":2134,"url":"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2022\/03\/02852_MSD_Logo_W-Anthem_Vertical_TealGrey_RGB.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.mymsd.ch\/fr\/succinctstatement\/keytruda\/","url":"https:\/\/www.mymsd.ch\/fr\/succinctstatement\/keytruda\/","name":"Information professionnelle KEYTRUDA\u00ae (pembrolizumab) - MyMSD.ch FR","isPartOf":{"@id":"https:\/\/www.mymsd.ch\/fr\/#website"},"datePublished":"2024-08-13T13:09:29+00:00","dateModified":"2026-04-10T14:14:43+00:00","breadcrumb":{"@id":"https:\/\/www.mymsd.ch\/fr\/succinctstatement\/keytruda\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.mymsd.ch\/fr\/succinctstatement\/keytruda\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.mymsd.ch\/fr\/succinctstatement\/keytruda\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.mymsd.ch\/fr\/"},{"@type":"ListItem","position":2,"name":"Product Succinct Statement","item":"https:\/\/www.mymsd.ch\/fr\/succinctstatement\/"},{"@type":"ListItem","position":3,"name":"Information professionnelle KEYTRUDA\u00ae (pembrolizumab)"}]},{"@type":"WebSite","@id":"https:\/\/www.mymsd.ch\/fr\/#website","url":"https:\/\/www.mymsd.ch\/fr\/","name":"MyMSD.ch FR","description":"","publisher":{"@id":"https:\/\/www.mymsd.ch\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.mymsd.ch\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.mymsd.ch\/fr\/#organization","name":"MSD Switzerland","url":"https:\/\/www.mymsd.ch\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.mymsd.ch\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2023\/10\/cropped-myMSD-logo.png","contentUrl":"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2023\/10\/cropped-myMSD-logo.png","width":4084,"height":692,"caption":"MSD Switzerland"},"image":{"@id":"https:\/\/www.mymsd.ch\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/pages\/96249","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/users\/73173"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/comments?post=96249"}],"version-history":[{"count":12,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/pages\/96249\/revisions"}],"predecessor-version":[{"id":104404,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/pages\/96249\/revisions\/104404"}],"up":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/pages\/96214"}],"wp:attachment":[{"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/media?parent=96249"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/categories?post=96249"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tags?post=96249"},{"taxonomy":"ga4_page_audience","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_audience?post=96249"},{"taxonomy":"ga4_page_birn_id","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_birn_id?post=96249"},{"taxonomy":"ga4_page_branding","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_branding?post=96249"},{"taxonomy":"ga4_page_businessunit","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_businessunit?post=96249"},{"taxonomy":"ga4_page_campaign","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_campaign?post=96249"},{"taxonomy":"ga4_page_content_purpose","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_content_purpose?post=96249"},{"taxonomy":"ga4_page_customer_journey_stage","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_customer_journey_stage?post=96249"},{"taxonomy":"ga4_page_customer_specialty","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_customer_specialty?post=96249"},{"taxonomy":"ga4_page_experience","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_experience?post=96249"},{"taxonomy":"ga4_page_indication","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_indication?post=96249"},{"taxonomy":"ga4_page_material_intent","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_material_intent?post=96249"},{"taxonomy":"ga4_page_product","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_product?post=96249"},{"taxonomy":"ga4_page_region","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_region?post=96249"},{"taxonomy":"ga4_page_therapeuticarea","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_therapeuticarea?post=96249"},{"taxonomy":"tx-therapeutic-area","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tx-therapeutic-area?post=96249"},{"taxonomy":"tx-product","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tx-product?post=96249"},{"taxonomy":"tx-pathology","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tx-pathology?post=96249"},{"taxonomy":"tx-content-type","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tx-content-type?post=96249"},{"taxonomy":"tx-active-ingredient","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tx-active-ingredient?post=96249"},{"taxonomy":"access","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/access?post=96249"},{"taxonomy":"user_status","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/user_status?post=96249"},{"taxonomy":"user_role","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/user_role?post=96249"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}